Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer
While the curative approach to gastric cancer includes perioperative regimens in several countries, a substantial proportion of patients may not receive treatment prior to surgery. This study examines the adjuvant provision of chemoradiotherapy (CRT) for non-pretreated patients with cancer of the stomach including the gastric cardia.
All surgically treated patients with primary adenocarcinoma of the stomach and gastric cardia diagnosed between January 2004–December 2013 were selected from the Netherlands Cancer Registry. Patients who did not receive neoadjuvant treatment were included. Early gastric cancers (cT1), postoperative deaths within 90 days, patients with metastatic disease (M1), patients who received adjuvant chemotherapy and patients with macroscopic tumor after surgery (R2) were excluded.
Some 3277 patients underwent surgery, and 99 patients (3%) received adjuvant CRT. Treatment was more often administered in patients with a younger age (<65 years) and a high socioeconomic status (SES), in case of non-cardia cancer, positive lymph nodes, and positive resection margins (R1). Median survival time was 28 months (95% CI 17–39), compared to 35 months (95% CI 33–38) in CRT-naïve patients. After adjustment for confounders, a small net benefit for adjuvant CRT was found (hazard ratio, HR: 0.75, 95% CI 0.58–0.96). In subgroup analyses, benefit was most pronounced for patients with seven or more lymph metastases.
Marginal survival benefit was observed for adjuvant CRT in gastric cancer patients who did not receive neoadjuvant treatment. Treatment could be considered for patients with disease involving nodal invasion and those left with microscopic residual disease after surgery.
The authors thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for collecting data in the Netherlands Cancer Registry (NCR).
Compliance with Ethical Standards
All procedures followed were in accordance with the ethical standards of the national supervisory committee of the Netherlands Cancer Registry (NCR) and with the Helsinki Declaration of 1964 and later versions.
Informed consent or substitute for it was obtained from all patients for being included in the study.
- 4.Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi57–63.Google Scholar
- 8.Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.CrossRefPubMedGoogle Scholar
- 14.Kofoed SC, Muhic A, Baeksgaard L, Jendresen M, Gustafsen J, Holm J, et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scandinavian J Surg. 2012;101(1):26–31.Google Scholar
- 16.Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol. 2000;11(7):837–43.CrossRefPubMedGoogle Scholar
- 19.Jacome AA, Wohnrath DR, Scapulatempo Neto C, Fregnani JH, Quinto AL, Oliveira AT, et al. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer. 2013;16(2):233–8.Google Scholar
- 21.Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. ICD-O international classification of diseases for oncology. Geneva: World Health Organization; 2000.Google Scholar
- 22.Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. international union against cancer (UICC). Chichester: Wiley-Blackwell; 2010.Google Scholar
- 23.Sobin LH, Wittekind C. TNM classification of malignant tumours. International Union Against Cancer (UICC). New York: Wiley-Liss; 2002.Google Scholar
- 24.Tesser PTM, van Praag CS, van Dugteren FA, Herweijer LJ, van der Wouden HC. Rapportage minderheden 1995: concentratie en segregatie. Rijswijk: Sociaal en Cultureel Planbureau, 1995.Google Scholar
- 28.Enestvedt CK, Diggs BS, Shipley DK, Thomas CR, Billingsley KG. A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results? Gastrointest Cancer Res: GCR. 2009;3(6):233–8.PubMedPubMedCentralGoogle Scholar
- 30.Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63(5):1279–85.CrossRefPubMedGoogle Scholar
- 34.Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329.CrossRefPubMedPubMedCentralGoogle Scholar